/ Eli Lilly


The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it
/ Earnings, Market Analysis

The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it

Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.

July 12, 2024
LLY vs NVO: Which One is Likely to Become a $1T Company First

LLY vs NVO: Which One is Likely to Become a $1T Company First

Tackling growing waistlines is expected to yield much shareholder value.

February 08, 2024
Pfizer’s Stock is Down 44% YTD as Woes Continue

Pfizer’s Stock is Down 44% YTD as Woes Continue

Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug.

December 01, 2023
LLY and NOVO Report Strong Earnings But Are Vulnerable to Q4 Headwinds

LLY and NOVO Report Strong Earnings But Are Vulnerable to Q4 Headwinds

Eli Lilly and Novo Nordisk continue to capitalize on unprecedented interest for weight-loss drugs, with both companies posting strong Q3 results on Thursday.

November 02, 2023
421 Stocks Out of the S&P 500 Are Down Since July; These 3 Bucked the Trend

421 Stocks Out of the S&P 500 Are Down Since July; These 3 Bucked the Trend

With Big Tech underperforming, some stocks enjoy double-digit gains.

October 25, 2023